Latest N30 Pharma Stories
BOULDER, Colo., March 2, 2011 /PRNewswire/ -- N30 Pharmaceuticals, LLC (N30 Pharma) today announced it will present data at the 2011 Annual Meeting of the Society of Toxicology in Washington, D.C. on Monday, March 7, 2011.
BOULDER, Colo., Sept. 8 /PRNewswire/ -- N30 Pharmaceuticals, LLC today announced it has dosed the first human subject with N6022, a first-in-class inhibitor of s-nitrosoglutathione reductase (GSNOR). N6022 is the first GSNOR inhibitor to be administered to human beings.
BOULDER, Colo., Aug. 2 /PRNewswire/ -- N30 Pharmaceuticals, LLC today announced the approval of its Investigational New Drug Application for N6022 by the U.S. Food and Drug Administration.
BOULDER, Colo., May 11 /PRNewswire/ -- N30 Pharma (N30), a biopharmaceutical company focused on the discovery and development of a new class of proprietary therapeutics that conserve endogenous, bioactive nitric oxide, announced today that it has completed a $10 million financing and expanded its Board of Directors. Joining the Company's Board of Directors will be Dr.
BOULDER, Colo., April 6 /PRNewswire/ -- N30 Pharma today announced the formation of its Scientific Advisory Board, or SAB.
BOULDER, Colo., March 23 /PRNewswire/ -- N30 Pharma (N30) today announced that Joseph Loscalzo, M.D., PhD., has joined the Board of Directors of the Company. Dr.